Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant chemoradiotherapy with sequential ipilimumab and nivolumab in rectal cancer (CHINOREC)
2019-003865-17Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ipilimumab and nivolumab in rectal cancer (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Safety, tolerability and feasibility. Started Nov 2019; status: completed.
02
Drugs
ipilimumabnivolumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2019-003865-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003865-17.